NDMA on good manufacturing practices
Executive Summary
In June 14 comments to FDA on its Feb. 12 proposal to change certain CGMP requirements for finished drugs, the Nonprescription Drug Manufacturers Association recommended that FDA drop the requirement for annual examination of reserve samples for evidence of deterioration. NDMA argues that other methods such as stability studies, shelf-life studies, and complaint investigations can provide adequate stability information on products.